---
document_datetime: 2026-01-06 10:46:05
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/bildyos-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: bildyos-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.318669
conversion_datetime: 2026-01-10 11:14:40.264085
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.1
  docling: 2.67.0
  docling-core: 2.58.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Bildyos

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                     |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------|
| Variation type IB /  | C.I.2 Change(s) in the Summary of Product | 05/01/2026                          |                                             | SmPC                             | To update Section 4.4 of the SmPC regarding |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000317750                                       | Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a (Type IB) - To update Section 4.4 of the SmPC regarding treatment discontinuation following assessment of the same change for the reference product Prolia.   |            |            |                        | treatment discontinuation following assessment of the same change for the reference product Prolia.   |
|---------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------|
| Marketing Authorisation Transfer - H / EMA/T/0000302034 | - Transfer of a marketing authorisation - transfer of marketing authorisation from Henlius Europe GmbH to Sciencepharma Sp. z o.o.                                                                                                                                                                                                                                                                                                                               | 15/10/2025 | 06/11/2025 | SmPC, Labelling and PL |                                                                                                       |